Related Experiment Video
Updated: Jul 1, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Development of chimeric antigen receptor (CAR)-T cells targeting A56 viral protein implanted by oncolytic virus
Euna Cho1, Min Ho An2,3, Yi Sle Lee1
1Research Center, Bionoxx Inc., Seongnam-si, Gyeonggi-do 13554, Republic of Korea.
Abstract:
To address the challenge of solid tumor targeting in CAR-T therapy, we utilized the A56 antigen, which is uniquely expressed on a diverse range of cancer cells following the systemic administration of an oncolytic vaccinia virus (OVV). Immunohistochemical assays precisely confirmed exclusive localization of A56 to tumor tissues. In vitro studies demonstrated a distinct superiority of A56-dependent CAR-T cytotoxicity across multiple cancer cell lines. Building on these in vitro observations, we strategically administered A56 CAR-T cells, OVV, and hydroxyurea (HU) combination in HCT-116 tumor-bearing non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice, leading to a significant reduction in tumor size and an extended time to progression. Consequently, A56-targeting combinatorial immunotherapy provides the benefit of reducing inadvertent CAR-T effects on normal cells while preserving its effectiveness against cancer cells. Furthermore, our approach of implanting A56 via OVV on tumors facilitates a wide therapeutic application of CAR-T cells across various solid tumors.
Insights
This study introduces a novel CAR-T therapy targeting the A56 antigen, expressed on tumors after oncolytic vaccinia virus (OVV) treatment. This approach enhances cancer cell killing while sparing healthy tissues, improving solid tumor treatment.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- CAR-T therapy faces challenges in targeting solid tumors effectively.
- The A56 antigen is uniquely expressed on cancer cells post-oncolytic vaccinia virus (OVV) administration.
- Targeting tumor-specific antigens is crucial for CAR-T efficacy and safety.
Purpose of the Study:
- To develop a novel CAR-T therapy targeting the A56 antigen for solid tumors.
- To evaluate the efficacy and safety of A56-targeting CAR-T cells in combination with OVV and hydroxyurea (HU).
- To demonstrate the potential of this combinatorial approach for broad application in solid tumor treatment.
Main Methods:
- Immunohistochemical assays to confirm A56 antigen localization.
- In vitro studies assessing A56-dependent CAR-T cell cytotoxicity against various cancer cell lines.
- In vivo studies using HCT-116 tumor-bearing NOD/SCID mice treated with A56 CAR-T cells, OVV, and HU.
Main Results:
- A56 antigen was exclusively localized to tumor tissues.
- A56-dependent CAR-T cells showed superior cytotoxicity against multiple cancer cell lines in vitro.
- Combination therapy significantly reduced tumor size and prolonged time to progression in mice.
Conclusions:
- A56-targeting combinatorial immunotherapy effectively targets solid tumors while minimizing off-tumor effects.
- OVV-mediated A56 antigen expression provides a versatile platform for CAR-T cell therapy in diverse solid tumors.
- This strategy offers a promising avenue for improving CAR-T therapy outcomes in cancer patients.
